| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2023 | 5.26% | Morgan Stanley | $57 → $60 | Maintains | Equal-Weight |
| 10/26/2023 | 0% | BMO Capital | $50 → $57 | Maintains | Outperform |
| 10/25/2023 | 5.26% | Barrington Research | $50 → $60 | Maintains | Outperform |
| 10/25/2023 | 0% | Morgan Stanley | $52 → $57 | Maintains | Equal-Weight |
| 08/16/2023 | -12.28% | Barrington Research | → $50 | Reiterates | Outperform → Outperform |
| 08/16/2023 | -8.77% | Morgan Stanley | $50 → $52 | Maintains | Equal-Weight |
| 08/16/2023 | -12.28% | BMO Capital | $49 → $50 | Maintains | Outperform |
| 04/26/2023 | -12.28% | Morgan Stanley | $46 → $50 | Maintains | Equal-Weight |
| 04/14/2023 | -12.28% | Barrington Research | → $50 | Reiterates | → Outperform |
| 03/10/2023 | -19.3% | Morgan Stanley | → $46 | Downgrades | Overweight → Equal-Weight |
| 01/26/2023 | -15.79% | BMO Capital | $47 → $48 | Maintains | Outperform |
| 01/25/2023 | -12.28% | Barrington Research | → $50 | Reiterates | → Outperform |
| 01/25/2023 | -19.3% | Morgan Stanley | $41 → $46 | Maintains | Overweight |
| 01/04/2023 | -28.07% | Morgan Stanley | $43 → $41 | Maintains | Overweight |
| 10/27/2022 | -12.28% | BMO Capital | $52 → $50 | Maintains | Outperform |
| 10/27/2022 | -24.56% | Morgan Stanley | $47 → $43 | Maintains | Overweight |
| 09/27/2022 | -17.54% | Morgan Stanley | $45 → $47 | Maintains | Overweight |
| 08/25/2022 | -21.05% | Morgan Stanley | → $45 | Upgrades | Equal-Weight → Overweight |
| 08/10/2022 | -21.05% | Morgan Stanley | $42 → $45 | Maintains | Equal-Weight |
| 07/20/2022 | -26.32% | Morgan Stanley | $39 → $42 | Maintains | Equal-Weight |
| 04/20/2022 | -31.58% | Morgan Stanley | $36 → $39 | Maintains | Equal-Weight |
| 01/26/2022 | -36.84% | Morgan Stanley | $35 → $36 | Maintains | Equal-Weight |
| 01/05/2022 | -38.6% | Morgan Stanley | $34 → $35 | Maintains | Equal-Weight |
| 04/21/2021 | -49.12% | Morgan Stanley | $27 → $29 | Maintains | Equal-Weight |
| 02/02/2021 | -52.63% | Morgan Stanley | → $27 | Initiates Coverage On | → Equal-Weight |
| 09/04/2020 | — | Sidoti & Co. | Upgrades | Neutral → Buy | |
| 07/09/2020 | -40.35% | Sidoti & Co. | $30 → $34 | Downgrades | Buy → Neutral |
| 01/28/2020 | -59.65% | BMO Capital | $27 → $23 | Maintains | Outperform |
| 01/28/2020 | -47.37% | Sidoti & Co. | $36 → $30 | Maintains | Buy |
What is the target price for Stride (LRN)?
The latest price target for Stride (NYSE: LRN) was reported by Morgan Stanley on November 16, 2023. The analyst firm set a price target for $60.00 expecting LRN to rise to within 12 months (a possible 5.26% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Stride (LRN)?
The latest analyst rating for Stride (NYSE: LRN) was provided by Morgan Stanley, and Stride maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Stride (LRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stride, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stride was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.
Is the Analyst Rating Stride (LRN) correct?
While ratings are subjective and will change, the latest Stride (LRN) rating was a maintained with a price target of $57.00 to $60.00. The current price Stride (LRN) is trading at is $57.00, which is within the analyst's predicted range.